Investigating ALN-HSD for MASH with Genetic Risk
This study is looking at an investigational drug called ALN-HSD to treat Metabolic Dysfunction-Associated Steatohepatitis (MASH) in adults. MASH is a chronic liver disease where fat buildup causes inflammation and scarring (fibrosis) in the liver, which can lead to serious liver problems. This study is for people aged 18 to 75 who have MASH with moderate to severe scarring (F2 or F3) and a specific genetic risk. Participants will receive either ALN-HSD or a placebo (an inactive substance). The main goal is to see if ALN-HSD can reduce liver scarring over 52 weeks.
- Study design
- This interventional study plans to enroll 120 participants. It compares ALN-HSD to a placebo to see its effects.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at week 52, suggesting participants will be followed for at least this duration.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
At a glance
Conditions
NCT05519475
Where you'd take part
This study runs at 71 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Adobe Clinical Research
Tucson, Arizonano site contact published
Recruiting
Advanced Medical Trials
Georgetown, Texasno site contact published
Recruiting
American Research Corporation
Austin, Texasno site contact published
Recruiting
American Research Corporation at The Texas Liver Institute
San Antonio, Texasno site contact published
Recruiting
Arizona Liver Health
Chandler, Arizonano site contact published
Recruiting
Arizona Liver Health - Tucson
Tucson, Arizonano site contact published
Recruiting
Ark Clinical Research - Fountain Valley
Fountain Valley, Californiano site contact published
Recruiting
Ark Clinical Research - Long Beach
Long Beach, Californiano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in quantitative liver Fibrosis (qFibrosis)Baseline to week 52
Change in the continuous qFibrosis score measured by second harmonic generation/two-photon excitation microscopy